Journal article
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, J Bull, E Leong, A Simpson, G Kannourakis, PA Francis, J Chirgwin, E Abdi, V Gebski, AS Veillard, D Zannino, N Wilcken, L Reaby, DF Lindsay, HD Badger, JF Forbes
Breast | CHURCHILL LIVINGSTONE | Published : 2014
Abstract
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy. Methods: Female patients with operable breast cancer that was clinically T2 (≥3cm) or T3-4, N0-1, M0 were enrolled to receive 24 weeks of neoadjuvant chemotherapy using epirubicin and cyclopho..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
We thank the women who participated in the study, their doctors and the research teams at each of the participating hospitals; the Australia and New Zealand Breast Cancer Trials Group ANZ 0502 Study Team; the NeoGem steering committee, and the National Health and Medical Research Council of Australia (project grant ID 455513). Roche Products, Pty Limited (Australia) (drug, research grants), Eli Lilly Australia (drug, research grant), Sanofi-Aventis (drug), supported the trial and commented on findings of this study, but had no input into data analysis or interpretation.